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TGF-β (transforming growth factor-β) is well identified as a central mediator in renal
fibrosis. TGF-β initiates canonical and non-canonical pathways to exert multiple biological
effects. Among them, Smad signaling is recognized as a major pathway of TGF-β
signaling in progressive renal fibrosis. During fibrogenesis, Smad3 is highly activated,
which is associated with the down-regulation of an inhibitory Smad7 via an ubiquitin
E3-ligases-dependent degradation mechanism. The equilibrium shift between Smad3
and Smad7 leads to accumulation and activation of myofibroblasts, overproduction of
ECM (extracellular matrix), and reduction in ECM degradation in the diseased kidney.
Therefore, overexpression of Smad7 has been shown to be a therapeutic agent for
renal fibrosis in various models of kidney diseases. In contrast, another downstream
effecter of TGF-β/Smad signaling pathway, Smad2, exerts its renal protective role by
counter-regulating the Smad3. Furthermore, recent studies demonstrated that Smad3
mediates renal fibrosis by down-regulating miR-29 and miR-200 but up-regulating miR-
21 and miR-192. Thus, overexpression of miR-29 and miR-200 or down-regulation of
miR-21 and miR-192 is capable of attenuating Smad3-mediated renal fibrosis in various
mouse models of chronic kidney diseases (CKD). Taken together, TGF-β/Smad signaling
plays an important role in renal fibrosis. Targeting TGF-β/Smad3 signaling may represent
a specific and effective therapy for CKD associated with renal fibrosis.
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Introduction
The TGF-β superfamily consists of highly pleiotropic molecules including activins, inhibins, BMPs
(Bone morphogenic proteins), GDFs (Growth differentiation factors) and GDNFs (Glial-derived
neurotrophic factors), and exerts multiple biological functions in renal inflammation, fibrosis, cell
apoptosis, and proliferation (Massague and Wotton, 2000). Among them, TGF-β is known as a
key pro-fibrotic mediator in fibrotic diseases. Three isoforms of TGF-β have been identified in
mammals, termed TGF-β1, 2, and 3, of which TGF-β1 is the most abundant isoform and can be
produced by all types of renal resident cells. After synthesis, TGF-β1 is released in association with
LAP (latency-associated peptide) as a latent form of TGF-β1 which binds to LTBP (Latent TGF-β-
binding protein) in the target tissues. When exposed to multiple types of stimuli, including ROS
(Reactive oxygen species), plasmin and acid (Lyons et al., 1990; Munger et al., 1999; Meng et al.,
2013), TGF-β1 can be released from the LAP and LTBP and becomes active. The active TGF-β1
then binds to TβRII (Type II TGF-β receptor), a constitutively active kinase, which recruits TβRI
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(Type I TGF-β receptor) and phosphorylates the downstream
receptor-associated Smads (R-Smads) i.e., Smad2 and Smad3
(Wrana et al., 1994). Then the phosphorylated Smad2 and Smad3
form an oligomeric complex with a common Smad, Smad4, and
translocates into the nucleus to regulate the transcription of tar-
get genes in collaboration with various co-activators and co-
repressors. It is interesting that an inhibitory Smad, Smad7, can
be induced in a Smad3-dependent manner. Smad7 consequently
competes with the R-Smads for binding to the activated recep-
tors, in order to exert its negative effect on TGF-β/Smad sig-
naling (Shi and Massague, 2003). Additionally, TGF-β1 is able
to function through the Smad-independent pathways, including
p38, ERK (Extracellular-signal-regulated kinase), MAPK, Rho-
GTPases, Rac, Cdc42, ILK (Integrin linked kinase) (Attisano and
Wrana, 2002; Derynck and Zhang, 2003; Li et al., 2009; Loeﬄer
andWolf, 2014). In this review, we focus on the pathological roles
of TGF-β/Smad signaling in renal fibrosis.
Role of TGF-β1 in Renal Fibrosis
Renal fibrosis, characterized by excessive deposition of ECM
(Extracellular matrix), is recognized as a common pathological
feature of CKD (Chronic kidney diseases) which leads to the
development of ESRD (End-stage renal disease), accompanied by
a progression of renal malfunctions (Eddy and Neilson, 2006).
Although effective therapy for renal fibrosis is still lacking, a
number of studies demonstrated that TGF-β is the key mediator
in CKD associated with progressive renal fibrosis. It is well docu-
mented that TGF-β1 has multiple biological properties including
cell proliferation, differentiation, apoptosis, autophagy, produc-
tion of ECM, etc. (Meng et al., 2013). Considerable evidence
revealed that TGF-β is substantially upregulated in the injured
kidney on both patients and animal disease models (Yamamoto
et al., 1996; Bottinger and Bitzer, 2002). It is also showed that
the urinary levels of TGF-β are significantly increased in patients
with various renal diseases, which is positively correlated with the
degree of renal fibrosis (Murakami et al., 1997). Moreover, the
importance of TGF-β1 in renal fibrosis is further supported by
the findings that overexpression of active TGF-β1 in rodent liver
is capable of inducing the fibrotic response in kidney; whereas
blocking TGF-β with neutralizing antibody, antisense oligonu-
cleotides, inhibitors, or genetic deletion of receptors can atten-
uate kidney fibrosis in vivo and in vitro (Sanderson et al., 1995;
Kopp et al., 1996; Border and Noble, 1998; Moon et al., 2006;
Petersen et al., 2008; Meng et al., 2012a). In contrast to the
active form of TGF-β1, the latent form of TGF-β1 can pro-
tect the kidney against fibrosis and inflammation by upregulat-
ing Smad7 that is observed in the latent TGF-β transgenic mice
received with UUO-induced nephropathy or anti-GBM-induced
glomerulonephritis (Huang et al., 2008a,b). Taken together, TGF-
β exerts profibrotic effects on the kidney through several pos-
sible mechanisms: (1) TGF-β1 directly induces the produc-
tion of ECM, including collagen I and fibronectin, through the
Smad3-dependent or -independent mechanisms (Samarakoon
et al., 2012); (2) TGF-β1 suppresses the degradation of ECM
by inhibiting MMPs (Matrix metalloproteinases) but inducing
TIMPs (Tissue inhibitor of metalloproteinase) and the natural
inhibitor of MMPs; (3) TGF-β1 is believed to play critical roles
in the transdifferentiation toward myofibroblast of several types
of cells, including epithelial cells, endothelial cells, and pericytes,
although the origin of myofibroblast is still undefined (Meng
et al., 2013; Wu et al., 2013); (4) TGF-β1 acts directly on dif-
ferent types of renal resident cells, for example: it can promote
the proliferation of mesangial cells in order to increase matrix
production, or induce the elimination of tubular epithelial cells
and podocytes which may lead to a deterioration of renal injury
and incur more severe renal fibrosis (Bottinger and Bitzer, 2002;
Lopez-Hernandez and Lopez-Novoa, 2012) (Figure 1).
Role of Smads in Renal Fibrosis
Smad2 and Smad3
It is consistently demonstrated that Smad2 and Smad3 are exten-
sively activated in the fibrotic kidney in patients and animal mod-
els with CKD (Meng et al., 2013). Although Smad2 and Smad3
share more than 90% similarity in their amino acid sequences,
their functional roles in renal fibrosis are distinct. It is well doc-
umented that Smad3 is pathogenic since knockout of Smad3
gene inhibits fibrosis in obstructive nephropathy (Sato et al.,
2003), diabetic nephropathy (Fujimoto et al., 2003), hyperten-
sive nephropathy (Liu et al., 2012), and drug-toxicity-related
nephropathy (Zhou et al., 2010). Of note, Smad3 promotes renal
fibrosis by directly binding to the promoter region of colla-
gens to trigger their production (Vindevoghel et al., 1998; Chen
et al., 1999), and inhibiting the ECM degradation via induc-
tion of TIMP-1 while reducing MMP-1 activities in fibroblasts
(Yuan and Varga, 2001). In contrast to Smad3, Smad2 is unable to
directly bind to the genomic DNA (Dennler et al., 1998). Previous
study suggested that roles of Smad2 and Smad3might be different
in fibrotic diseases (Piek et al., 2001; Yang et al., 2003b; Phan-
ish et al., 2006). Consistent with the finding that the endogenous
ratio of Smad2 and Smad3may ultimately influence the cytostatic
function of Smad3 (Kim et al., 2005), results from our recent
study demonstrated that conditional knockout of Smad2 from
tubular epithelial cells enhances Smad3-mediated renal fibrosis
in vivo and in vitro,which is associated with the increase in phos-
phorylation and nuclear translocation of Smad3, promotion of
the Smad3 responsive promoter activity, and binding of Smad3
to Col1A2 promoter (Meng et al., 2010).
Smad4
As a common Smad for TGF-β/BMP signaling, Smad4 plays
a critical role in nucleocytoplasmic shuttling of Smad2/3 and
Smad1/5/8 complexes (Massague and Wotton, 2000). It has been
demonstrated that loss of Smad4 in mesangial cells inhibits TGF-
β1-induced ECM deposition (Tsuchida et al., 2003), which is fur-
ther confirmed by our recent finding that specific deletion of
Smad4 from renal tubular epithelial cells attenuates the UUO-
induced renal fibrosis by suppressing Smad3 responsive pro-
moter activity and decreasing the binding of Smad3 to the target
genes independent of its phosphorylation and nuclear transloca-
tion (Meng et al., 2012b).
Smad7
As an inhibitory regulator in the TGF-β/Smad signaling path-
way, Smad7 can be induced by a Smad3-dependent mechanism,
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FIGURE 1 | Role of TGF-β/Smad signaling in kidney disease. TGF-β1 signals through the downstream mediators to exert its biological activities on different cell
types of kidney cells during renal inflammation and fibrosis.
which in turn blocks the signal transduction of TGF-β1 via
its negative feedback loop (Afrakhte et al., 1998; Zhu et al.,
1999; Kavsak et al., 2000; Ebisawa et al., 2001). Moreover, the
regulatory mechanism of Smad7 on TGF-β signaling occurs
in an elegant manner, i.e., TGF-β not only induces Smad7
transcription, but also promotes the degradation of Smad7
by activating the Smad3-dependent Smurfs/arkadia-mediated
ubiquitin–proteasome degradation pathway (Kavsak et al., 2000;
Ebisawa et al., 2001; Fukasawa et al., 2004; Liu et al., 2008). In
this setting, the level of Smad7 protein is significantly reduced in
response to the high level of active TGF-β1 in CKD. Most impor-
tantly, the functional role of Smad7 is further defined by the
findings that deletion of Smad7 accelerates renal fibrogenesis in
obstructive nephropathy, diabetic nephropathy as well as hyper-
tensive nephropathy (Chung et al., 2009; Chen et al., 2011; Liu
et al., 2013), suggesting Smad7 as a therapeutic agent for treat-
ment of CKD (Lan et al., 2003; Hou et al., 2005; Ka et al., 2007,
2012; Chen et al., 2011; Liu et al., 2014).
Collectively, compelling evidence indicates that hyperactiva-
tion of Smad3 associated with progressive degradation of Smad7,
is a key feature of renal fibrotic diseases. More importantly, the
imbalance of Smad3 and Smad7 was proved to be one of the
major mechanisms in mediating the fibrotic response. In this
regard, rebalancing the disturbed Smad3/Smad7 ratio, through
downregulating Smad3 and upregulating Smad7 simultaneously,
seems to be an effective strategy for treatment of renal fibrosis.
Role of TGF-β in Transdifferentiation of
Myofibroblasts
Emerging evidence suggests that the accumulation of myofibrob-
lasts, a predominant source for ECM production, is a critical
step in the progression of renal fibrosis (Wynn and Ramalingam,
2012). However, the origin of myofibroblast is still controver-
sial. It has been reported that myofibroblasts may be derived
from the resident fibroblasts, pericytes, bone marrow cells (e.g.,
fibrocytes), epithelial cells (Epithelial–mesenchymal transition,
EMT), and endothelial cells (Endothelial–mesenchymal transi-
tion, EndMT) (Allison, 2013; LeBleu et al., 2013; Meng et al.,
2014). Our latest data also revealed that bone marrow-derived
macrophages were capable of becomingmyofibroblast phenotype
via a process of macrophage-myofibroblast transition (MMT)
in patients and UUO model with active renal fibrosis (Nikolic-
Paterson et al., 2014). In addition, it is generally accepted that
local fibroblasts can differentiate into myofibroblast under the
stimulation of TGF-β (Evans et al., 2003; Midgley et al., 2013).
Increasing evidence indicates that fibrocytes can produce a large
amount of collagens directly in response to the stimulus such as
TGF-β (Hong et al., 2007; Wada et al., 2007). Administration
of TGF-β promotes the transdifferentiation of epithelial cells
and endothelial cells toward myofibroblast-like cells, whereas,
blockade of TGF-β/Smad signaling with inhibitors or antagonists
attenuates or reverses the process of EMT or EndMT (Fan et al.,
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1999; Zeisberg et al., 2003, 2008; Li et al., 2010; Liu, 2010; Yang
et al., 2010; Xavier et al., 2014). In addition, TGF-β1 can pro-
mote renal fibrosis via the cell-cell interaction mechanism as
TGF-β1 released from the injured epithelium is able to activate
pericyte-myofibroblast transition (Wu et al., 2013). Moreover, we
also identify that advanced glycation end products (AGEs) and
angiotensin II are capable of activating Smad3 to mediate the
process of EMT under diabetes and hypertension conditions (Li
et al., 2003, 2004; Wang et al., 2006b; Yang et al., 2009, 2010;
Chung et al., 2010b).
Role of TGF-β1/Smad-dependent miRNAs
in Renal Fibrosis
Increasing evidence demonstrates that TGF-β1 can also regulate
several miRNAs to facilitate renal fibrogenesis. As illustrated in
Figure 2, TGF-β1 up-regulates miR-21, miR192, miR-377, miR-
382, and miR-491-5p, but down-regulates miR-29 and miR-200
families during renal fibrosis (Kantharidis et al., 2011; Kriegel
et al., 2012; Lan and Chung, 2012; Chung et al., 2013a,b). In
fibrotic kidneys, the level of miR-21 is highly induced (Godwin
et al., 2010; Zhong et al., 2011, 2013; Chau et al., 2012; Xu et al.,
2012; Wang et al., 2013), whereas inhibition of miR-21 attenu-
ates deposition of ECM and halts the progression of renal fibrosis
(Zhong et al., 2011, 2013; Chau et al., 2012). Role of miR-192 in
fibrosis is still controversial. It is reported that miR-192 is ele-
vated in fibrotic mouse models and TGF-β1-treated murine cells
(Kato et al., 2007; Chung et al., 2010a; Putta et al., 2012). Knock-
out or knockdown of miR-192 largely attenuated renal fibro-
sis possibly through induction of ZEB1/2 in vivo and in vitro.
FIGURE 2 | Regulation of TGF-β/Smad3 in fibrosis-related microRNAs
during renal fibrosis. TGF-β1 activates Smad3 that binds directly to a
number of microRNAs to either negatively or positively regulate their
expression and function in renal fibrosis.
However, a recent study indicated that TGF-β1 reduces miR-192
expression in human TECs and deficiency of miR-192 accelerates
renal fibrosis in diabetic nephropathy (Krupa et al., 2010), which
is further evident by the results from the renal biopsy of dia-
betic patients with lower level of miR-192 (Wang et al., 2010).
The discrepancy in these studies suggests the complexity of miR-
192 in renal fibrogenesis. The miR-29 and miR-200 are TGF-β1-
dependent anti-fibrotic miRNAs that are extensively suppressed
in the diseased kidneys (Qin et al., 2011). Of note, more than 20
ECM-related genes, including collagens, are potential targets for
miR-29 where some of them are regulated by the TGF-β signal-
ing (van Rooij et al., 2008; Xiao et al., 2012). Overexpression of
miR-29 attenuates renal fibrosis in vivo in obstructive and dia-
betic nephropathies and suppresses the fibrotic genes in vitro in
response to various stimuli including TGF-β1, high glucose or
salt-induced hypertensive conditions (Du et al., 2010; Liu et al.,
2010; Qin et al., 2011; Chen et al., 2014). The miR-200 family
contains miR-200a, miR-200b, miR-200c, miR-429, and miR-141
(Howe et al., 2012). Downregulation of miR-200a and miR-141
are detected in the fibrotic kidneys of obstructive and diabetic
nephropathies (Wang et al., 2011; Xiong et al., 2012). As miR-
200 has a major role in maintaining the epithelial differentiation,
delivery of miR-200b significantly reduces renal fibrotic response
by suppressing the transcriptional repressors of E-cadherin ZEB1
and ZEB2 (Korpal et al., 2008; Oba et al., 2010).
TGF-β/Smad Signaling as a Therapeutic
Potential for Renal Fibrosis
General Blockade of TGF-β Signaling
The therapeutic potential of anti-TGF-β1 therapy has beenwidely
tested according to the pathogenic role of TGF-β1 in fibrogenesis.
It has been shown that TGF-β neutralizing antibodies, antisense
TGF-β oligodeoxynucleotides, soluble human TβRII (sTβRII.Fc)
and specific inhibitors to TβR kinases (such as GW788388 and
IN-1130) can effectively halt the progression of renal fibrosis in
a number of experimental kidney disease models. A recent study
also demonstrated that blockade of TGF-β1 receptor posttrans-
lational core fucosylation can attenuate renal interstitial fibrosis
(Shen et al., 2013). In addition, some TGF-β inhibitors have been
further tested in preclinical or clinical trials (Tampe and Zeis-
berg, 2014). For an instance, treatment with Pirfenidone, a small
molecule that blocks TGF-β1 promoter, can prevent the decline
of eGFR (estimated glomerular filtration rate) in patients with
focal segmental glomerulosclerosis (FSGS) or diabetic nephropa-
thy (Cho et al., 2007; Sharma et al., 2011). In addition, Fresoli-
mumab and LY2382770, neutralizers for TGF-β1 activity, are also
tested in FSGS and diabetic kidney diseases in human (Tracht-
man et al., 2011; Choi et al., 2012; Tampe and Zeisberg, 2014).
However, the major obstacle and risk for these potential therapies
by generally blocking TGF-β signalingmay be related to the abro-
gation of its anti-inflammatory and anti-tumorigenesis prop-
erty. Nevertheless, it should be mentioned that TGF-β1 may also
serve as a potential biomarker for renal fibrosis, since significant
upregulation of urine TGF-β1 have been detected in progressive
renal diseases (Tsakas and Goumenos, 2006).
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FIGURE 3 | Potential therapeutic strategies for renal fibrosis by
specifically targeting downstream TGF-β/Smad signaling. Since renal
fibrosis is mediated positively by Smad3 but negatively by Smad7,
treatment for renal fibrosis can target Smad3 with specific inhibitors or
Smad3-dependent microRNAs that regulate fibrosis, and/or by promoting
Smad7 with gene therapy or specific agonists.
Specific Inhibition of Downstream Smads or
Smad-regulated miRNAs
In order to avoid the side effects caused by complete block-
ade of TGF-β1 signaling, more focus has been paid on inhibit-
ing the downstream targets of this signaling pathway including
Smad3, Smad7, and Smad-dependent miRNAs (Ng et al., 2009).
As shown in Figure 3, SIS3, a specific inhibitor of Smad3 phos-
phorylation, can attenuate renal fibrosis in diabetic nephropa-
thy (Li et al., 2010). Accumulated evidence shows that target-
ing Smad3 by overexpressing renal Smad7 produces inhibitory
effects on both renal inflammation and fibrosis in a variety of
kidney disease models (Hou et al., 2005; Ka et al., 2007, 2012;
Chen et al., 2011; Liu et al., 2014). Moreover, recent studies
also revealed that overexpression of miR-29, miR-200 or inhibi-
tion of miR-21 and miR-192 can effectively decelerate the pro-
gression of renal fibrosis (Oba et al., 2010; Chung et al., 2010a;
Qin et al., 2011; Zhong et al., 2011, 2013; Chen et al., 2014)
(Figure 3).
BMP-7 is a natural antagonist for TGF-β through inhibit-
ing the TGF-β/Smad3, which has been demonstrated on vari-
ous renal disease models (Hruska et al., 2000; Zeisberg et al.,
2003; Wang et al., 2006a; Sugimoto et al., 2007; Luo et al., 2010;
Meng et al., 2013). Klotho, a single-pass transmembrane pro-
tein predominantly expressed in renal tubular epithelial cells,
is capable of suppressing renal fibrosis by directly binding to
type II TGF-β receptor to block the TGF-β-initiated signaling
(Doi et al., 2011). Most recently, a study showed that an adap-
tor protein, Kindlin-2, recruits Smad3 to TGF-β type I receptor,
therefore contributing to TGF-β/Smad3-mediating renal inter-
stitial fibrosis (Wei et al., 2013). In addition, two well-known
Smad transcriptional co-repressors Ski (Sloan-Kettering Institute
proto-oncogene) and SnoN (Ski-related novel gene, non Alu-
containing), elicit their anti-fibrotic effects on TGF-β by antag-
onizing Smad-mediated gene transcription (Yang et al., 2003a).
Moreover, GQ5, a small molecular phenolic compound extracted
from dried resin of Toxicodendron vernicifluum, has been shown
to inhibit the interaction between TGF-β type I receptor and
Smad3 through interfering the binding of Smad3 to SARA,
thereby reducing the phosphorylation of Smad3 and downregu-
lating the transcription of downstream fibrotic indexes including
α-SMA, collagen I and fibronectin in vivo and in vitro (Ai et al.,
2014). Furthermore, a number of miRNAs, such as let-7b and
miR-29, are capable of regulating TGF-β signaling and altering
the progression of renal fibrosis (Kato et al., 2011; Xiao et al.,
2012; Wang et al., 2014).
Conclusion
An equilibrium shift of TGF-β/Smad signaling due to the hyper-
activation of Smad3 but reduction of Smad7 may be a key patho-
logical mechanism leading to renal fibrogenesis. Thus, rebal-
ancing the TGF-β/Smad signaling by targeting Smad3 activity,
up-regulating Smad7, as well as specifically modulating Smad3-
dependent miRNAs related to fibrosis may represent an effective
therapy for CKD associated with progressive real fibrosis.
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